Try
AMGEN INC
AMGNUnited States
72 filed reports · 460 financial concepts · 41 earnings calls · 11 media appearances
Filed reports
72 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 370 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 31 | 328 | Jun 2018 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 31 | 5,603 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 6,070 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 439 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 12 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 1, 2026 | 325 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 13, 2026 | 1,172 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 3, 2026 | 8 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 314 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 4, 2025 | 8 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 191 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 5, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 2, 2025 | 191 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 1, 2025 | 8 | Open |
Financial data
460 concepts · 12,001 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial432 concepts · 9,420 facts · Mar 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Goodwill (US GAAP)58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Amortization of intangible assets57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Interest expense debt57 · Dec 2014 to Jun 2026
- Nonoperating income expense57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent57 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in accrued income taxes payable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other operating assets56 · Dec 2014 to Jun 2026
- Increase decrease in other operating liabilities56 · Dec 2014 to Jun 2026
- Net cash provided by used in financing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in investing activities56 · Dec 2014 to Jun 2026
Product4 concepts · 2,052 facts · Dec 2014 to Jun 2026
- Revenue2,029 · Dec 2014 to Jun 2026
- Revenue (including assessed tax)12 · Dec 2020 to Dec 2022
- Revenue (excluding assessed tax)10 · Dec 2021
- Gain loss on oil and gas hedging activity1 · Dec 2016
Guidance6 concepts · 346 facts · Jul 2018 to Aug 2026
- Capital Expenditures Guidance76 · Jul 2018 to Aug 2026
- Revenue Guidance62 · Jul 2018 to Aug 2026
- Effective Tax Rate Guidance58 · Jul 2018 to Aug 2026
- EPS (Diluted) Guidance58 · Jul 2018 to Aug 2026
- Effective Tax Rate Guidance (Adjusted (non-GAAP))46 · Jul 2018 to Aug 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))46 · Jul 2018 to Aug 2026
Segment12 concepts · 110 facts · Mar 2024 to Jun 2026
- Revenue24 · Mar 2024 to Jun 2026
- Cost of goods and services sold (US GAAP)8 · Mar 2024 to Jun 2026
- General and administrative expense (US GAAP)8 · Mar 2024 to Jun 2026
- Income tax expense benefit8 · Mar 2024 to Jun 2026
- Interest expense debt8 · Mar 2024 to Jun 2026
- Investment income interest8 · Mar 2024 to Jun 2026
- Net income loss8 · Mar 2024 to Jun 2026
- Research and development expense software excluding acquired in process cost8 · Mar 2024 to Jun 2026
- Royalty expense8 · Mar 2024 to Jun 2026
- Segment reporting other item amount8 · Mar 2024 to Jun 2026
- Selling and marketing expense (US GAAP)8 · Mar 2024 to Jun 2026
- Income loss from equity method investments6 · Mar 2024 to Sep 2025
Geography6 concepts · 73 facts · Dec 2014 to Dec 2025
- Property, Plant & Equipment, Net33 · Dec 2015 to Dec 2025
- Revenue32 · Dec 2014 to Dec 2025
- PUERTO RICO3 · Mar 2017 to Mar 2018
- Revenue (excluding assessed tax)2 · Dec 2021
- Revenue (including assessed tax)2 · Dec 2017
- Puerto Rico1 · Dec 2016
Segments
2,235 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis35 members · 1,948 facts
- Product143 · Dec 2016 to Jun 2026
- Aranesp141 · Dec 2016 to Jun 2026
- Enbrel141 · Dec 2016 to Jun 2026
- Prolia141 · Dec 2016 to Jun 2026
- Xgeva141 · Dec 2016 to Jun 2026
- Other Products138 · Dec 2016 to Jun 2026
- Kyprolis123 · Dec 2017 to Jun 2026
- Otezla114 · Dec 2018 to Jun 2026
- Repathaevolocumab108 · Dec 2018 to Jun 2026
- Neulasta90 · Dec 2016 to Dec 2022
- Nplate87 · Dec 2019 to Jun 2026
- Product And Service Other67 · Dec 2016 to Jun 2026
- EVENITY66 · Mar 2022 to Jun 2026
- BLINCYTO57 · Dec 2021 to Jun 2026
- KRYSTEXXA57 · Dec 2021 to Jun 2026
- TEPEZZA57 · Dec 2021 to Jun 2026
- Vectibix57 · Dec 2021 to Jun 2026
- TEZSPIRE54 · Dec 2022 to Jun 2026
- Epogen45 · Dec 2016 to Dec 2019
- Sensipar Mimpara45 · Dec 2016 to Dec 2019
- Other products13 · Dec 2020 to Dec 2022
- Evenity12 · Dec 2020 to Dec 2023
- IMDELLTRAIMDYLLTRA12 · Mar 2025 to Jun 2026
- UPLIZNA12 · Mar 2025 to Jun 2026
- KYPROLIS9 · Dec 2023 to Dec 2025
- Repatha9 · Dec 2023 to Dec 2025
- Aranesp1 · Dec 2021
- Enbrel1 · Dec 2021
- Evenity1 · Dec 2021
- Kyprolis1 · Dec 2021
- Nplate1 · Dec 2021
- Otezla1 · Dec 2021
- Prolia1 · Dec 2021
- Repathaevolocumab1 · Dec 2021
- Xgeva1 · Dec 2021
Statement business segments1 member · 110 facts
- Reportable110 · Mar 2024 to Jun 2026
Product or serviceus-gaap:ProductOrServiceAxis15 members · 104 facts
- Aranesp10 · Dec 2014 to Mar 2018
- Enbrel10 · Dec 2014 to Mar 2018
- Epogen10 · Dec 2014 to Mar 2018
- Neulasta10 · Dec 2014 to Mar 2018
- Prolia10 · Dec 2014 to Mar 2018
- Sensipar Mimpara10 · Dec 2014 to Mar 2018
- Xgeva10 · Dec 2014 to Mar 2018
- Other Products6 · Mar 2017 to Mar 2018
- BLINCYTO4 · Dec 2014 to Dec 2017
- Kyprolis4 · Dec 2014 to Dec 2017
- NEUPOGEN4 · Dec 2014 to Dec 2017
- Nplate4 · Dec 2014 to Dec 2017
- Other Countries4 · Dec 2014 to Dec 2017
- Repatha4 · Dec 2014 to Dec 2017
- Vectibix4 · Dec 2014 to Dec 2017
Statement geographicalus-gaap:StatementGeographicalAxis7 members · 41 facts
- Pr11 · Dec 2015 to Dec 2025
- Us11 · Dec 2015 to Dec 2025
- US6 · Dec 2014 to Mar 2018
- PR4 · Dec 2016 to Mar 2018
- ROW4 · Dec 2014 to Dec 2017
- Row3 · Dec 2015 to Dec 2017
- Non Us2 · Mar 2017 to Mar 2018
Statement geographicalsrt:StatementGeographicalAxis5 members · 32 facts
- Non Us10 · Dec 2016 to Dec 2025
- US10 · Dec 2016 to Dec 2025
- Rest of world8 · Dec 2017 to Dec 2025
- Us2 · Dec 2017 to Dec 2021
- Non us2 · Dec 2017 to Dec 2021
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary224 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary253 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes20 claims from 1 reports · Dec 2025
- Risk factors59 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1Apr 30, 2026
- FY2025 Q4Feb 3, 2026
- FY2025 Q3Nov 4, 2025
- FY2025 Q2Aug 5, 2025
- FY2025 Q1May 1, 2025
- FY2024 Q4Feb 4, 2025
- FY2024 Q3Oct 30, 2024
- FY2024 Q2Aug 6, 2024
- FY2024 Q1May 1, 2024
- FY2023 Q4Feb 6, 2024
- FY2023 Q3Oct 31, 2023
- FY2023 Q2Aug 3, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Jan 31, 2023
- FY2022 Q3Nov 3, 2022
Executive media
11 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews5 · Jan 2021 to Jan 2026
- Other appearances3 · Oct 2020 to Jun 2026
- Podcasts2 · Jun 2023 to Jan 2024
- Conference talks1 · Jun 2024
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.